NCT01031524已完成1 期
Randomized Double-blind Controlled Phase I/IIa Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (282-383) to Protect Against Artificial Challenge With P. Falciparum
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy
研究概览
简要总结
Phase I/IIa double-blind randomized (adjuvant)-controlled trial. 16 volunteers are randomized to receive two doses of either 30 µg of PfCS102 formulated in Montanide ISA 720 (verum) or ISA 720 alone (control), 60 days apart. Two weeks after the 2nd immunization, 14 volunteers are challenged with bites of 5 infected mosquitoes using the NF54 strain of P. falciparum. The main outcome will be the length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy performed twice a day.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •resident in or near Lausanne;
- •age >18 and <45 years;
- •written informed consent;
- •>10/12 correct responses to the questionnaire of understanding.
排除标准
- •history of malaria; possible exposure to malaria within the previous 6 months;
- •positive serology for PfCS102by ELISA;
- •history of severe reactions or allergy to mosquito bites, artemether/lumefantrine (Riamet®) or vaccines;
- •pregnant or lactating female;
- •any confirmed or suspected immunodeficient condition;
- •seropostivity for HIV;
- •chronic or active neurological, gastrointestinal, cardio-vascular or respiratory disease;
- •hemoglobinopathies;
- •history of >2 hospitalisations for invasive bacterial infections;
- •requirement of any chronic medication;
- •suspected or known current alcohol or illegal drug abuse (excluding cannabis);
- •any other significant finding which, in the opinion of the investigator, would significantly increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the study;
- •a body mass index < 18kg/m2 or > 32 kg/m2;
- •evidence of past or present psychiatric condition;
- •seropositivity for HIV, hepatitis C or B (other than HBs Ab);
- •10-year risk of coronary heart disease <10%;
- •any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis.
结局指标
主要结局
Length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy
时间窗: 1month
次要结局
- Incidence of adverse events(15 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1FibromyalgiaNCT04748705Virios Therapeutics, Inc.422
已完成
1 期
Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult SubjectsHealthyNCT04872231TFF Pharmaceuticals, Inc.65
已完成
1 期
Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy VolunteersHelicobacter Pylori Infected SubjectsHelicobacter Pylori Naive SubjectsNCT03270800ImevaX72
终止
1 期
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisSclerosis, MultipleAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesNCT03540485Fundación Pública Andaluza para la gestión de la Investigación en Sevilla25
Unknown
不适用
A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.Chronic RhinitisNCT01546662Enovate Biolife Pvt Ltd54